The survival queries revealed that for the 161 patients with glioma that showed > 2.0-fold up-regulation of CD9, there was a 50% shorter median survival, compared to the group of seven glioma patients with 2.0-fold down-regulation of CD9 (Figure 5B, left; 24 months vs. 48 months, respectively; p = 0.04). This evidence concerns the gene CD9 and central nervous system cancer.